Abstracts tagged "rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)"

Abstract Number: 79 • 2014 ACR/ARHP Annual Meeting
PECAM-1 GENE Polymorphisms and Soluble PECAM-1 LEVEL in Rheumatoid Arthritis and Systemic LUPUS Erythematosus Patients Is There a Link with Clinical Atherosclerotic Events?
Omer Nuri Pamuk¹, Hilmi Tozkir², Mehmet Sevki Uyanik³, Hakan Gurkan⁴, Julide Duymaz⁴, Salim Donmez⁵, Metin Yazar² and Gulsum Pamuk³, ¹Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, ²Genetics, Trakya University Medical Faculty, EDIRNE, Turkey, ³Hematology, Trakya University Medical Faculty, Edirne, Turkey, ⁴Trakya University Medical Faculty, EDIRNE, Turkey, ⁵Department of Rheumatology, Trakya University School of Medicine, Edirne, Turkey
Background/Purpose: Platelet-endothelial cell adhesion molecule-1 (PECAM-1/CD31) which plays a role in the transmigration of leucocytes into tissues is a member of the immunoglobulin (Ig) superfamily.…
Abstract Number: 2032 • 2013 ACR/ARHP Annual Meeting
How Does Age At Onset Influence Autoimmune Rheumatic Diseases?
Jenny Amaya-Amaya¹, Juan-Camilo Sarmiento-Monroy², Nicolás Molano-González¹, Mónica Rodríguez-Jiménez¹, Rubén-Darío Mantilla², Adriana Rojas-Villarraga¹ and Juan-Manuel Anaya², ¹Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, ²School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia
Background/Purpose: Age at onset of disease (AOD) refers to the time period at which a patient experiences the first sign (s) and symptom(s). AOD varies…
Abstract Number: 1844 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis, Sjogren’s Syndrome and Systemic Lupus Erythematosus Patients Have a Distinct Spectrum Of Serum Anticytokine Autoantibodies
Sarthak Gupta^1,2, Ioanna P. Tatouli³, Lindsey B. Rosen², Sarfaraz A. Hasni¹, Richard M. Siegel¹, Steven M. Holland², Haralampos M. Moutsopopoulos³ and Sarah K. Browne², ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ³School of Medicine, National University of Athens, Athens, Greece
Background/Purpose: Anticytokine autoantibodies are pathogenic in many hematologic, pulmonary and infectious diseases. However, the prevalence and significance of anticytokine autoantibodies in rheumatic conditions is poorly…
Abstract Number: 2048 • 2012 ACR/ARHP Annual Meeting
Four Physician Global Assessments for Overall Status, Inflammation, Damage, and Unexplained Symptoms Are Useful in Usual Care of Patients with Osteoarthritis, Fibromyalgia, Systemic Lupus Erythematosus, and Spondyloarthropathy, As Well As Rheumatoid Arthritis
Isabel Castrejón¹, Martin J. Bergman² and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Taylor Hospital, Ridley Park, PA
Background/Purpose: A physician global estimate (DOCGL) is important in clinical decisions concerning patients with rheumatoid arthritis (RA), and often is the most efficient of the…
Abstract Number: 1811 • 2012 ACR/ARHP Annual Meeting
On the Origin of the Type I Interferon Signature in Rheumatoid Arthritis
T.D. de Jong¹, Saskia Vosslamber¹, Maija-Leena Eloranta², Lars Rönnblom², Kyra Gelderman¹, Mary von Blomberg¹, Irene Bultink³, Alexandre Voskuyl⁴ and Cornelis L. Verweij¹, ¹Pathology, VU University Medical Center, Amsterdam, Netherlands, ²Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, ³Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Presence of a type I interferon (IFN) signature has been described for several autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).…
Abstract Number: 1759 • 2012 ACR/ARHP Annual Meeting
Expression of Surface APRIL and Its Receptor, TACI, Is Upregulated On B Cells From Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients
Abby Jones Weldon¹, Sheri Hsu², Seyed K. Nazeri³, Saru Sachdeva², Jennifer Gonzalez⁴, Andrea D. Parra⁵, Abigail Benitez¹, Keith K. Colburn⁶, Ioana Moldovan⁷ and Kimberly J. Payne⁸, ¹Microbiology and Molecular Genetics, Loma Linda University, Loma Linda, CA, ²Rheumatology, Loma Linda University Medical Center, Loma Linda, CA, ³Rheumatology, Loma Lida University Medical Center, Loma Lida, CA, ⁴Center of Health Disparities and Molecular Medicine, Loma Linda University, Loma Linda, CA, ⁵Center for Health Disparities and Molecular Medicine, Loma Linda University, Loma Linda, CA, ⁶Dept Med - Rheum Sect, Loma Linda Univ Medical Center, Loma Linda, CA, ⁷Loma Linda Univ Medical Center, Loma Linda, CA, ⁸Pathology and Human Anatomy, Loma Linda University, Loma Linda, CA
Background/Purpose: Autoimmune disease affects more than 23 million Americans. Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA) are chronic, systemic B-cell mediated autoimmune diseases. During…
Abstract Number: 1038 • 2012 ACR/ARHP Annual Meeting
Assessment of Aortic Stiffness by Cardiac Magnetic Resonance Imaging in Systemic Autoimmune Rheumatic Diseases
Galia Karp¹, Arik Wolak², Nina Baram³, Victor Novack⁴, Philip Rosen³, Yael Perl⁵, Talia Wolak⁶, Ilan Shelef³ and Mahmoud Abu-Shakra⁷, ¹Medicine and Rheumatology, Department of Medicine, Soroka Medical Centre and Ben Gurion University, Beer-Sheva, Israel, ²Cardiology and and MRI Unit, Dept. of Cardiology, Cardiac MRI unit, Soroka University Medical Center, and Ben Gurion University, Beer-Sheva, Israel, ³Radiology division, Soroka University Medical Center and Ben Gurion University, Radiology division, Soroka University Medical Center and Ben Gurion University, ⁴Department of Medicine and Clinical Research center, Department of Medicine, Clinical Research center, Soroka University Medical Center and Ben Gurion University, ⁵Department of Medicine and Clinical Research center, Clinical Research center, Soroka University Medical Center and Ben Gurion University, ⁶Department of Medicine and Hypertension unit, Soroka University Medical Center and Ben-Gurion University, Department of Medicine and Hypertension unit, Soroka University Medical Center and Ben-Gurion University, ⁷Medicine and Rheumatology, Department of Medicine and Rheumatology, Soroka Medical Centre and Ben Gurion University, Beer-Sheva, Israel
Background/Purpose: Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis (RA) are known to cause premature arterial aging and early atherosclerosis hence leading to increased stiffness of…
Abstract Number: 991 • 2012 ACR/ARHP Annual Meeting
MTHFR Polymorphisms in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Associations with Intima Media Thickness Scores
Clio P. Mavragani¹, Maira Giannelou², Ioanna Papadaki³, Eleni Antypa⁴, Dimitrios Ioakeimidis⁵, Haralampos M. Moutsopoulos² and Michael Koutsilieris⁶, ¹Department of Experimental Physiology, School of Medicine, University of Athens, Athens, Greece, Athens, Greece, ²Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece, ³Department of Rheumatology, General Hospital of Athens "G.Gennimatas", Athens, Greece, ⁴Department of Radiology, General Hospital of Athens, Greece, ⁵Department of Rheumatology, General Hospital, Greece, ⁶Department of Physiology, Athens University Medical School, Athens, Greece
Background/Purpose: Previous studies identified polymorphisms in the gene coding for the Methylenetetrahydrofolatereductase (MTHFR) enzyme as genetic contributors for cardiovascular disease in the general population. The…
Abstract Number: 675 • 2012 ACR/ARHP Annual Meeting
Differential Impairment of Serum Cholesterol Efflux Capacity in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus
Pier Luigi Meroni¹, Nicoletta Ronda², Elda Favari³, Orietta Borghi⁴, Francesca Zimetti⁵, Mariapia Adorni⁶, Francesca Ingegnoli⁷, Maria Gerosa⁸, Claudia Grossi⁹ and Franco Bernini⁶, ¹Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, ²Department of Pharmacy, University of Parma, Parma, Italy, ³Department of Pharmacological and Biological Sciences,, University of Parma, Parma, Italy, ⁴Department of clinical and comunity sciences, University of Milan, Milan, Italy, ⁵Department of Pharmacological and Biological Sciences, University of Parma, Parma, Italy, ⁶Department of Pharmacological and Biological Sciences, 39-02-58318176, Parma, Italy, ⁷Dept. of clinical and community science, Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, ⁸Department of Clinical Sciences and Community Health, University of Milan, Italy, Division of Rheumatology, Istituto Ortopedico Gaetano Pini,, Milan, Italy, ⁹Lab of immunology, IRCCS Istituto Auxologico Italiano, Milano, Italy
Background/Purpose: Accelerated atherosclerosis associated with autoimmune diseases is partly due to immune system dysregulation aggravating cardiovascular damage, but little is known on lipid metabolism derangement…
Abstract Number: 440 • 2012 ACR/ARHP Annual Meeting
Effects of Fetal Microchimerisms On Disease Onset and Severity in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus
Marianne Kekow¹, Sara Fill Malfertheiner², Maria Barleben¹, Susanne Drynda³, Joern Kekow³ and Thomas Brune¹, ¹Univ of Magdeburg, Children's Hospital, Magdeburg, Germany, ²Univ of Magdeburg, Department of Obstetrics and Gynecology, Magdeburg, Germany, ³Clinic of Rheumatology, Univ of Magdeburg, Vogelsang-Gommern, Germany
Background/Purpose: The major source of naturally acquired microchimerisms (MC) is the transplacental traffic of fetal cells between a mother and the fetus during pregnancy. Fetal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].